Ralph Pantophlet

List of Publications by Year
in descending order

50	4,218	218677 26	189892 50
papers	citations	h-index	g-index

57	57	57	3953
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. Journal of Infectious Diseases, 2023, 227, 838-849.	4.0	31
2	Synthetic Neoglycoconjugates of Heptaâ€•and Nonamannoside Ligands for Eliciting Oligomannoseâ€Specific HIVâ€1â€Neutralizing Antibodies. ChemBioChem, 2022, 23, .	2.6	0
3	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	4.0	65
4	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	6.0	64
5	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Journal of Infectious Diseases, 2022, 226, 983-994.	4.0	26
6	HIV-1 Entry and Prospects for Protecting against Infection. Microorganisms, 2021, 9, 228.	3.6	5
7	A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies. Scientific Reports, 2021, 11, 4637.	3.3	3
8	Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies. Scientific Reports, 2020, 10, 7582.	3.3	11
9	Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike. Journal of the American Chemical Society, 2019, 141, 7946-7954.	13.7	19
10	Comparative Antigenicity of Thiourea and Adipic Amide Linked Neoglycoconjugates Containing Modified Oligomannose Epitopes for the Carbohydrate-Specific anti-HIV Antibody 2G12. Bioconjugate Chemistry, 2019, 30, 70-82.	3.6	15
11	Effect of buffer composition on PNAâ€“RNA hybridization studied in the microfluidic microarray chip. Canadian Journal of Chemistry, 2018, 96, 241-247.	1.1	10
12	Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides. Journal of Organic Chemistry, 2017, 82, 12346-12358.	3.2	18
13	Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Nature Communications, 2017, 8, 1601.	12.8	33
14	Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. PLoS ONE, 2015, 10, e0125575.	2.5	13
15	Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Glycobiology, 2015, 25, 412-419.	2.5	27
16	The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. Virology, 2014, 462-463, 98-106.	2.4	1
17	2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies. Journal of Virology, 2013, 87, 2234-2241.	3.4	18
18	Complex binding sites made to order. Nature Biotechnology, 2012, 30, 154-155.	17.5	1

#	Article	IF	Citations
19	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine, 2012, 30, 922-930.	3.8	27
20	A Bacterial Lipooligosaccharide that Naturally Mimics the Epitope of the HIV-Neutralizing Antibody 2G12 as a Template for Vaccine Design. Chemistry and Biology, 2012, 19, 254-263.	6.0	33
21	Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site. Journal of Virology, 2011, 85, 9039-9050.	3.4	49
22	Antibody Epitope Exposure and Neutralization of HIV-1. Current Pharmaceutical Design, 2010, 16, 3729-3743.	1.9	17
23	Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds. Chemistry and Biology, 2010, 17, 357-370.	6.0	125
24	The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions. Journal of Virology, 2009, 83, 1649-1659.	3.4	24
25	Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology, 2008, 381, 251-260.	2.4	54
26	Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization. Journal of Molecular Biology, 2008, 375, 969-978.	4.2	71
27	A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. Journal of Virology, 2008, 82, 6359-6368.	3.4	112
28	Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies. Journal of Virology, 2007, 81, 8533-8542.	3.4	25
29	Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. Journal of Virology, 2007, 81, 6548-6562.	3.4	181
30	Structure of a High-affinity â€œMimotopeâ€•Peptide Bound to HIV-1-neutralizing Antibody b12 Explains its Inability to Elicit gp120 Cross-reactive Antibodies. Journal of Molecular Biology, 2007, 369, 696-709.	4.2	65
31	Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology, 2007, 364, 441-453.	2.4	65
32	GP120: Target for Neutralizing HIV-1 Antibodies. Annual Review of Immunology, 2006, 24, 739-769.	21.8	404
33	Differential Roles of CD14 and Toll-like Receptors 4and 2 in MurineAcinetobacterPneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 122-129.	5.6	166
34	Comparing Antigenicity and Immunogenicity of Engineered gp120. Journal of Virology, 2005, 79, 12148-12163.	3.4	96
35	A Dominant Role for CD8 + -T-Lymphocyte Selection in Simian Immunodeficiency Virus Sequence Variation. Journal of Virology, 2004, 78, 14012-14022.	3.4	89
36	Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker. Journal of Virology, 2004, 78, 5651-5657.	3.4	27

#	Article	IF	Citations
37	Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends in Molecular Medicine, 2003, 9, 468-473.	6.7	43
38	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2003, 77, 642-658.	3.4	237
39	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design. Journal of Virology, 2003, 77, 5889-5901.	3.4	126
40	The Carbohydrate Epitope of the Neutralizing Anti-HIV-1 Antibody 2G12. Advances in Experimental Medicine and Biology, 2003, 535, 205-218.	1.6	65
41	Identification of Acinetobacter Isolates from Species Belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii Complex with Monoclonal Antibodies Specific for O Antigens of Their Lipopolysaccharides. Vaccine Journal, 2002, 9, 60-65.	3.1	9
42	The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of Î±1â†'2 Mannose Residues on the Outer Face of gp120. Journal of Virology, 2002, 76, 7306-7321.	3.4	664
43	O-Antigen Diversity among Acinetobacter baumannii Strains from the Czech Republic and Northwestern Europe, as Determined by Lipopolysaccharide-Specific Monoclonal Antibodies. Journal of Clinical Microbiology, 2001, 39, 2576-2580.	3.9	34
44	Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. Science, 2001, 293, 1155-1159.	12.6	870
45	Generation and Serological Characterization of Murine Monoclonal Antibodies against O Antigens from Acinetobacter Reference Strains. Vaccine Journal, 2001, 8, 825-827.	2.6	5
46	Chemical and antigenic structure of the O-polysaccharide of the lipopolysaccharides from two Acinetobacter haemolyticus strains differing only in the anomeric configuration of one glycosyl residue in their O-antigens. FEBS Journal, 1999, 263, 587-595.	0.2	18
47	Use of a Murine O-Antigen-Specific Monoclonal Antibody To IdentifyAcinetobacterStrains of Unnamed Genomic Species 13 Sensu Tjernberg and Ursing. Journal of Clinical Microbiology, 1999, 37, 1693-1698.	3.9	11
48	Specificity of Rabbit Antisera against Lipopolysaccharide of Acinetobacter. Journal of Clinical Microbiology, 1998, 36, 1245-1250.	3.9	28
49	Structural and Serological Characterisation of the O-Antigenic Polysaccharide of the Lipopolysaccharide from Acinetobacter Junii Strain 65. FEBS Journal, 1997, 245, 477-481.	0.2	31
50	Structural and Serological Characterisation of Two O-Specific Polysaccharides of Acinetobacter. FEBS Journal, 1996, 239, 602-610.	0.2	56